BeOne Medicines Ltd.
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines BRUKINSA — United States Revenue Growth YoY by Quarter
BRUKINSA — United States Revenue Growth YoY (%) (%)
BeOne Medicines BRUKINSA — United States Revenue Growth YoY: 30.5% in Q2 2026, down 12.1 pts from a year earlier. That is the lowest of the 16 quarters on record here.
Where the Q2 2026 figure comes from
“U.S. sales of BRUKINSA totaled $892.5 million in the second quarter, compared to $683.7 million in the prior-year period, representing growth of 30.5%, driven primarily by robust demand growth.”
Source: Form 10-Q (filed 2026-08-05) ↗
Reported in Form 10-Q / 10-K MD&A & Form 8-K Earnings Releases.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | BRUKINSA — United States Revenue Growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 30.5% | -12.1 pts | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 35.1% | -25.1 pts | Form 10-Q (filed 2026-05-06) ↗ |
| Q4 2025 | Dec 31, 2025 | 37.0% | -60.0 pts | Form 8-K (filed 2026-02-26) ↗ |
| Q3 2025 | Sep 30, 2025 | 46.6% | -39.9 pts | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 42.6% | -71.8 pts | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 60.2% | -93.1 pts | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2024 | Dec 31, 2024 | 97.0% | – | Form 8-K (filed 2025-02-27) ↗ |
| Q3 2024 | Sep 30, 2024 | 86.5% | -63.3 pts | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 114.4% | -38.5 pts | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 153.3% | +48.9 pts | Form 10-Q (filed 2024-05-08) ↗ |
| Q3 2023 | Sep 30, 2023 | 149.8% | -71.1 pts | Form 10-Q (filed 2023-11-09) ↗ |
| Q2 2023 | Jun 30, 2023 | 152.9% | -303.4 pts | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | 104.4% | – | Form 10-Q (filed 2023-05-04) ↗ |
| Q3 2022 | Sep 30, 2022 | 220.9% | – | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | 456.3% | – | Form 10-Q (filed 2022-08-08) ↗ |
| Q4 2021 | Dec 31, 2021 | 539.0% | – | Form 8-K (filed 2022-02-25) ↗ |
Cite this data
StockData. (2026). BeOne Medicines BRUKINSA — United States Revenue Growth YoY (%), quarterly Q4 2021–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/prod-brukinsa-us-yoy
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.